KINAXO and Daiichi Sankyo Sign Collaboration Agreement

01-Oct-2010 - Germany

KINAXO Biotechnologies GmbH and Daiichi Sankyo Company Limited entered a long-term partnership in cancer research. Under the agreement, Daiichi Sankyo will employ KINAXO’s technology platform to support the development of Daiichi Sankyo’s targeted cancer drugs. This will involve KINAXO applying its proprietary chemical proteomics technologies Cellular Target Profiling® and KinAffinity® as well as its phosphoproteomics technology PhosphoScout® within various research programs pursued at Daiichi Sankyo. Financial details of the agreement were not disclosed.

Axel Ullrich, Director at the Max Planck Institute for Biochemistry in Martinsried and KINAXO Board member commented: “To promote innovation in cancer therapy we need to better understand how targeted drugs interfere with de-regulated signaling in human malignancies. To this end, KINAXO has established a unique technology platform that allows comprehensive analysis of cancer signal transduction processes and their response to drug treatment. I am convinced that these innovative technologies will significantly contribute to the development of tomorrow’s cancer therapeutics.”

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...